These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 11502453)

  • 1. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
    Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
    Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F; Kaplan M; Soloway MS
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.
    Holliday EB; Kuban DA; Levy LB; Bolukbasi Y; Master P; Choi S; Nguyen Q; McGuire SE; Mahmood U; Frank SJ; Hoffman KE
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):389-394. PubMed ID: 28462945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
    Meyer F; Moore L; Bairati I; Lacombe L; Têtu B; Fradet Y
    J Urol; 1999 Dec; 162(6):2024-8. PubMed ID: 10569561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
    Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
    Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
    J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
    de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
    Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
    Alexander A; Crook J; Jones S; Malone S; Bowen J; Truong P; Pai H; Ludgate C
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):23-30. PubMed ID: 19395187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
    Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
    Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
    Hajili T; Ohlmann CH; Linxweiler J; Niklas C; Janssen M; Siemer S; Stoeckle M; Saar M
    BJU Int; 2019 Jan; 123(1):58-64. PubMed ID: 29772100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.
    Gleave ME; La Bianca SE; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    Urology; 2000 Aug; 56(2):289-94. PubMed ID: 10925096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
    Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
    Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
    Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
    Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
    Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
    Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
    Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.